ga('send', 'pageview');

The considerations listed below, although backed by international medical studies, require definitive validation by means of formal experimentation trials in accordance with current legislation in the country of application. This trial should be initiated in an urgent manner with the same expeditious procedures used for testing drugs considered to potentially counteract COVID-19.

The present terminology is deliberately simplified. Whilst a scientific discussion involves the presentation of thorough documentation, that is not the purpose of this page. For the disclosure of additional information, please complete our contact form.


Successful trials were performed on severe and critically ill patients with COVID-19 pneumonia in Wuhan China. These patients had been in ICU with severe breathlessness for an average of 3 weeks and experiencing no improvement with mechanical ventilator where used. It was at this point that HBOT was first administered. Patients underwent one HBOT session a day for 5 consecutive days. Breathlessness was entirely mitigated after the first HBOT treatment. Within 3 days, breathlessness disappeared. All patients recovered within an average of 4.6 HBOT sessions. This comprehensive study is also supported by a solid bibliography advocating the effectiveness of HBOT against COVID-19. Furthermore, the effectiveness of hyperbaric therapy against COVID-19 is an extension of the effectiveness proven against many other viruses such as (SARS-CoV1, HIV-AIDS).

For the time being, it would be sufficient to initiate national HBOT trials, during a period of a few days only, with asymptomatic or mild symptom patients to provide important data. Trials will then evolve towards symptomatic patients and those with pre-existing conditions, taking into account the precautions of the case. In the emergency context of COVID-19, numerous drugs have been tested without formal experimentation, and despite the risks of side effects on patients.

Basically not. The test requires the availability of a hyperbaric chamber and technicians, as well as the use of a limited number of suitable medical personnel supported by its already existing hospital facility. There is also a wide availability of positive patients at the moment.

In this moment of particular emergency, it is extremely difficult to get the attention of political administrative and healthcare representatives. Furthermore, the ordinary ways to access a medical trial are difficult, complex and incompatible with the current emergency context, especially for a small business that does not work with the health sector every. We need collaboration and not barriers.


As mentioned below, hyperbaric oxygen therapy can prevent the worsening of patient conditions, avoiding virus progression to the point where intensive care (ICU) is necessary.

A large number of patients can be treated and healed in a short period of time, halting the progression of symptoms and the spread of infection to others.

Hyperbaric oxygen therapy drastically reduces the number of patients hospitalized and the number of patients admitted to intensive care, thereby easing the strain on the healthcare system and lessening the number of highly specialized nurses and doctors required.

In addition to not necessitating expensive medicines but only oxygen, the HBOT chamber has an infinitely lower cost compared to the setting up and management of intensive care units.

Once a comprehensive verification of HBOT efficacy has been finalized, for people without counterindications, the hyperbaric chamber considerably reduces the danger and complications of COVID-19, allowing the resumption of normal activities and a reassessment/easing of containment measures in place.

In recent months, DRASS has already completed the project for the rapid and industrial construction of large-capacity and customized transportable chambers for the treatment of COVID-19 positive patients, whose construction and operation is much more effective and less expensive than other treatments currently being trialled.

Why Hyperbaric Oxygen Therapy (HBOT) is invaluable in the fight against COVID-19

If the virus was a master key, hyperbaric oxygen alters both the key and the lock so that the virus becomes unable to do damage. Medical language: HBOT (Hyperbaric Oxygen Therapy) increases nitric oxide, a gas molecule that alters the lipid structure (fats) of the virus and modifies the viral RNA. Doing so blocks the replication of the virus and prevents it from binding to the ACE2 receptor. This has been seen both for AIDS HIV and for SARS-CoV-1 responsible for SARS 2002-2003.

With respect to lung damage that leads to intensive care hospitalization with intubation, HBOT reduces and destroys the molecules (called cytokines, including interleukin 6) that feed inflammation responsible for respiratory failure.

Yes. In healthy people, the virus is normally eliminated by nitrogen monoxide and oxygen free radicals. Over 50% of the patients who died from COVID-19 had dysmetabolic (hypercholesterolaemia, diabetes) and/or cardiovascular diseases related to impaired normal endothelial function and reduced production of nitrogen monoxide. In patients with comorbidities, hyperbaric treatment restores (through the genetic expression of Nitric Oxide Synthase) the normal synthesis of nitrogen monoxide allowing the body to eliminate the virus as it does in a healthy person. This genetic activation (up-regulation) is reinforced by the implementation of a cycle of therapies.

The protocol includes five hyperbaric treatments, one per day for five consecutive days. It is necessary to experimentally verify the therapeutic dose (pressure, duration).

Currently 20% (1 out of 5) of SARS-CoV-2 positive people experience severe symptoms that require hospitalization or intensive care in ICU. We expect that SARS-CoV-2 positive patients, treated with hyperbaric therapy in a pre-hospitalization phase, and therefore with less severe symptoms, will not evolve towards serious symptoms or need to be admitted to intensive care. The outcome is dependent on the severity of pre-existing conditions (comorbidities) which can contribute to the deterioration of a patient’s health.